Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

47.46 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
33 34 Next >
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report. 
Via Benzinga
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock jumped late Monday after the online pharmacy beat expectations. 
Via Investor's Business Daily
Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results
From Hims & Hers
Via Business Wire
Decoding Hims & Hers Health's Options Activity: What's the Big Picture?
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million,... 
Via Benzinga
Smart Money Is Betting Big In HIMS Options
Via Benzinga
A Look Into Hims & Hers Health Inc's Price Over Earnings
Via Benzinga
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
This Is What Whales Are Betting On Hims & Hers Health
Via Benzinga
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
Disrupting pharmacies is just the start for Hims & Hers. 
Via The Motley Fool
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
From Hims & Hers
Via Business Wire
Decoding 6 Analyst Evaluations For Hims & Hers Health
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
Via Benzinga
What Is Going On With Hims & Hers Stock?
Big GLP-1 news could have an impact. 
Via The Motley Fool
Top 3 Stocks Institutions Are Buying Right Now
Despite the stock market trading at new all-time highs, institutions still find enough reason to buy more enormous stakes in three stocks. 
Via MarketBeat
Hims & Hers Stock Dropped: Here's What You Need to Know
The GLP-1 drama continues at Hims & Hers. 
Via The Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
From Hims & Hers
Via Business Wire
Why Hims & Hers' Incredible Growth Will Continue
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. 
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
From Hims & Hers
Via Business Wire
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
An industry group sued the FDA, claiming tirzepatide remains in shortage. 
Via Investor's Business Daily
Topics Lawsuit
Where Does Hims & Hers Stock Go From Here?
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? 
Via The Motley Fool
2 Incredibly Cheap Growth Stocks to Buy Right Now
Look beyond the stock price at the business when shares are volatile. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Consistently investing even moderate sums can grow your portfolio with time. 
Via The Motley Fool
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree 
Via MarketBeat
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.